News & Events about Crinetics Pharmaceuticals Inc.
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials of CRN04894 in ACTH-...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). On ...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 December 1, 2022. ...
Globe Newswire
5 months ago
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, will be ...
Globe Newswire
5 months ago
Paltusotines Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushings Disease and Congenital Adrenal Hyperplasia CRN04777 and ...